Literature DB >> 3332182

The role of T-cells in preventing relapse in chronic myelogenous leukemia.

A Butturini1, R P Gale.   

Abstract

Bone marrow transplantation is effective in eradicating leukemia in over 90% of patients with chronic myelogenous leukemia (CML). This efficacy relates to some extent to the antileukemia effect of high-dose chemotherapy and radiation. An immune-mediated antileukemia effect of graft-versus-host disease is also important. In CML, a novel T-cell-mediated mechanism of leukemia eradication is also probably active. In this article we describe this novel mechanism, present preliminary data to support the notion and suggest that it might be exploited to treat CML in a context other than bone marrow transplantation.

Entities:  

Mesh：

Year:  1987        PMID： 3332182

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  6 in total

Review 1.  Graft versus leukemia.

Authors:  A Butturini; R P Gale
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.

Authors:  Jaebok Choi; Edward D Ziga; Julie Ritchey; Lynne Collins; Julie L Prior; Matthew L Cooper; David Piwnica-Worms; John F DiPersio
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

3.  Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.

Authors:  J K Orleans-Lindsay; L D Barber; H G Prentice; M W Lowdell
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

4.  In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

Authors:  Jaebok Choi; Julie Ritchey; Julie L Prior; Matthew Holt; William D Shannon; Elena Deych; David R Piwnica-Worms; John F DiPersio
Journal:  Blood       Date:  2010-04-27       Impact factor: 22.113

5.  Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine.

Authors:  Juanita Shaffer; Jean Villard; Terry K Means; Stephen Alexander; David Dombkowski; Bimalangshu R Dey; Steven McAfee; Karen K Ballen; Susan Saidman; Frederic I Preffer; David H Sachs; Thomas R Spitzer; Megan Sykes
Journal:  Exp Hematol       Date:  2007-07       Impact factor: 3.084

Review 6.  Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies.

Authors:  Sina Naserian; Mathieu Leclerc; Sara Shamdani; Georges Uzan
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.